GLP-1 Clinical Trials in Parkinson's Disease

Evidence quality

Highlighted claims

• Clinical results across GLP-1 receptor agonists in PD have been mixed, with some trials meeting primary endpoints and others failing. — Disease-modifying effect, safety and optimal dose of oral semaglutide tablets for patients with Parkinson’s disease (MOST-ABLE study): protocol for a randomised, double-blind, placebo-controlled study
• The overall pattern of positive preclinical and epidemiological evidence alongside inconclusive clinical data supports rigorous testing of a structurally distinct molecule delivered via a different route. — Disease-modifying effect, safety and optimal dose of oral semaglutide tablets for patients with Parkinson’s disease (MOST-ABLE study): protocol for a randomised, double-blind, placebo-controlled study
• The inconsistency between the phase 2 and phase 3 exenatide trials may reflect differences in injection device, dosing continuity, or patient subgroup composition. — Disease-modifying effect, safety and optimal dose of oral semaglutide tablets for patients with Parkinson’s disease (MOST-ABLE study): protocol for a randomised, double-blind, placebo-controlled study